BioGeneration Ventures (BGV) of the Netherlands has raised €150 million for a fifth venture fund which will enable it continue creating new biotech companies and provide financial support to those already building portfolios. BGV Fund V was oversubscribed, generating funds from existing and new investors, of which 78% were of US origin. Existing investors also contributed, including Eli Lilly and Co, Novo Holdings, and Bristol Myers Squibb Co. The fund’s close was announced on 13 July.
